Traditional implants in the gastrointestinal tract are meant to pass through a patient’s system, delivering a drug in short bursts or recording the health of a patient’s colon.
But in recent years, scientists have sought after ultra-long lasting ingestible devices that can deliver drugs for several weeks in a patient’s GI tract. Lyndra, Inc., a start-up based on such technology from the Massachusetts Institute of Technology, raised $23 million in April to support development of its star-shaped capsule.
Sustained-release drug delivery devices that reside in the gastrointestinal tract require a power source and, as gastroenterologist Giovanni Traverso told Drug Delivery Business News, batteries don’t make the cut.
Get the full story at our sister site, Drug Delivery Business News.
The post Powering the next generation of ingestible drug delivery devices appeared first on MassDevice.